A citation-based method for searching scientific literature

Anish Thomas, Nobuyuki Takahashi, Vinodh N Rajapakse, Xiaohu Zhang, Yilun Sun, Michele Ceribelli, Kelli M Wilson, Yang Zhang, Erin Beck, Linda Sciuto, Samantha Nichols, Brian Elenbaas, Janusz Puc, Heike Dahmen, Astrid Zimmermann, Jillian Varonin, Christopher W Schultz, Sehyun Kim, Hirity Shimellis, Parth Desai, Carleen Klumpp-Thomas, Lu Chen, Jameson Travers, Crystal McKnight, Sam Michael, Zina Itkin, Sunmin Lee, Akira Yuno, Min-Jung Lee, Christophe E Redon, Jessica D Kindrick, Cody J Peer, Jun S Wei, Mirit I Aladjem, William Douglas Figg, Seth M Steinberg, Jane B Trepel, Frank T Zenke, Yves Pommier, Javed Khan, Craig J Thomas. Cancer Cell 2021
Times Cited: 12







List of co-cited articles
67 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.
Eric E Gardner, Benjamin H Lok, Valentina E Schneeberger, Patrice Desmeules, Linde A Miles, Paige K Arnold, Andy Ni, Inna Khodos, Elisa de Stanchina, Thuyen Nguyen,[...]. Cancer Cell 2017
198
41

Comprehensive genomic profiles of small cell lung cancer.
Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco,[...]. Nature 2015
905
41

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Anish Thomas, Christophe E Redon, Linda Sciuto, Emerson Padiernos, Jiuping Ji, Min-Jung Lee, Akira Yuno, Sunmin Lee, Yiping Zhang, Lan Tran,[...]. J Clin Oncol 2018
58
33

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio,[...]. N Engl J Med 2018
33

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Timothy A Yap, Brent O'Carrigan, Marina S Penney, Joline S Lim, Jessica S Brown, Maria J de Miguel Luken, Nina Tunariu, Raquel Perez-Lopez, Daniel Nava Rodrigues, Ruth Riisnaes,[...]. J Clin Oncol 2020
41
33

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
M Catherine Pietanza, Saiama N Waqar, Lee M Krug, Afshin Dowlati, Christine L Hann, Alberto Chiappori, Taofeek K Owonikoko, Kaitlin M Woo, Robert J Cardnell, Junya Fujimoto,[...]. J Clin Oncol 2018
151
33

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, Richard T Penson, Susan T Schumer, L Austin Doyle, Elizabeth K Lee, Elise C Kohn, Linda R Duska, Marta A Crispens,[...]. Lancet Oncol 2020
42
25

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Junko Murai, Ying Feng, Guoying K Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier. Oncotarget 2016
131
25

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Benjamin H Lok, Eric E Gardner, Valentina E Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A Teicher, Nadeem Riaz, Simon N Powell,[...]. Clin Cancer Res 2017
143
25

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Triparna Sen, Pan Tong, C Allison Stewart, Sandra Cristea, Aly Valliani, David S Shames, Abena B Redwood, You Hong Fan, Lerong Li, Bonnie S Glisson,[...]. Cancer Res 2017
98
25

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Yu-Han Huang, Olaf Klingbeil, Xue-Yan He, Xiaoli S Wu, Gayatri Arun, Bin Lu, Tim D D Somerville, Joseph P Milazzo, John E Wilkinson, Osama E Demerdash,[...]. Genes Dev 2018
92
25

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Mark D Borromeo, Trisha K Savage, Rahul K Kollipara, Min He, Alexander Augustyn, Jihan K Osborne, Luc Girard, John D Minna, Adi F Gazdar, Melanie H Cobb,[...]. Cell Rep 2016
162
25

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Carl M Gay, C Allison Stewart, Elizabeth M Park, Lixia Diao, Sarah M Groves, Simon Heeke, Barzin Y Nabet, Junya Fujimoto, Luisa M Solis, Wei Lu,[...]. Cancer Cell 2021
70
25

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.
Jing Shan Lim, Alvaro Ibaseta, Marcus M Fischer, Belinda Cancilla, Gilbert O'Young, Sandra Cristea, Vincent C Luca, Dian Yang, Nadine S Jahchan, Cécile Hamard,[...]. Nature 2017
161
16

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
José Trigo, Vivek Subbiah, Benjamin Besse, Victor Moreno, Rafael López, María Angeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro,[...]. Lancet Oncol 2020
71
16

DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs.
Manqing Li, Elaine Kao, Dane Malone, Xia Gao, Jean Y J Wang, Michael David. Nat Struct Mol Biol 2018
39
16

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Nathalie Baize, Isabelle Monnet, Laurent Greillier, Margaux Geier, Hervé Lena, Henri Janicot, Alain Vergnenegre, Jacky Crequit, Regine Lamy, Jean-Bernard Auliac,[...]. Lancet Oncol 2020
18
16

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Gemma N Jones, Claire Rooney, Nicola Griffin, Martine Roudier, Lucy A Young, Antonio Garcia-Trinidad, Gareth D Hughes, Jeffrey R Whiteaker, Zena Wilson, Rajesh Odedra,[...]. Br J Cancer 2018
17
16

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Anna Minchom, Caterina Aversa, Juanita Lopez. Ther Adv Med Oncol 2018
61
16

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Andrew N Blackford, Stephen P Jackson. Mol Cell 2017
660
16

Drug resistance in cancer: an overview.
Genevieve Housman, Shannon Byler, Sarah Heerboth, Karolina Lapinska, Mckenna Longacre, Nicole Snyder, Sibaji Sarkar. Cancers (Basel) 2014
930
16

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A Yazinski, Valentine Comaills, Rémi Buisson, Marie-Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig,[...]. Genes Dev 2017
170
16

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Frank P Vendetti, Alan Lau, Sandra Schamus, Thomas P Conrads, Mark J O'Connor, Christopher J Bakkenist. Oncotarget 2015
125
16


New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
16

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Philip Lienau, Benjamin Bader, Ulf Bömer, Dieter Moosmayer, Uwe Eberspächer,[...]. Mol Cancer Ther 2020
46
16

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Philip M Reaper, Matthew R Griffiths, Joanna M Long, Jean-Damien Charrier, Somhairle Maccormick, Peter A Charlton, Julian M C Golec, John R Pollard. Nat Chem Biol 2011
384
16

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
Amy B Hall, Dave Newsome, Yuxin Wang, Diane M Boucher, Brenda Eustace, Yong Gu, Brian Hare, Mac A Johnson, Sean Milton, Cheryl E Murphy,[...]. Oncotarget 2014
109
16

ATM and ATR as therapeutic targets in cancer.
Anika Maria Weber, Anderson Joseph Ryan. Pharmacol Ther 2015
313
16

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
Luis I Toledo, Matilde Murga, Rafal Zur, Rebeca Soria, Antonio Rodriguez, Sonia Martinez, Julen Oyarzabal, Joaquin Pastor, James R Bischoff, Oscar Fernandez-Capetillo. Nat Struct Mol Biol 2011
326
16

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Frank Griesinger, Ellen E Korol, Sheena Kayaniyil, Nebibe Varol, Timo Ebner, Sarah M Goring. Lung Cancer 2019
32
16

SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J Vlachostergios, Michael Sigouros, Juan Miguel Mosquera,[...]. Mol Cancer Ther 2020
22
16

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Xueqian Gong, Jian Du, Stephen H Parsons, Farhana F Merzoug, Yue Webster, Philip W Iversen, Li-Chun Chio, Robert D Van Horn, Xi Lin, Wayne Blosser,[...]. Cancer Discov 2019
76
16

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Laura R Saunders, Alexander J Bankovich, Wade C Anderson, Monette A Aujay, Sheila Bheddah, KristenAnn Black, Radhika Desai, Paul A Escarpe, Johannes Hampl, Amy Laysang,[...]. Sci Transl Med 2015
285
16

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Nadia Terranova, Mendel Jansen, Martin Falk, Bart S Hendriks. Cancer Chemother Pharmacol 2021
5
40

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Claudia Winkler, Joshua Armenia, Gemma N Jones, Luis Tobalina, Matthew J Sale, Tudor Petreus, Tarrion Baird, Violeta Serra, Anderson T Wang, Alan Lau,[...]. Br J Cancer 2021
12
16

The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
Sarah M Pearsall, Sam Humphrey, Mitchell Revill, Derrick Morgan, Kristopher K Frese, Melanie Galvin, Alastair Kerr, Mathew Carter, Lynsey Priest, Fiona Blackhall,[...]. J Thorac Oncol 2020
16
16

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Junko Murai, Anish Thomas, Markku Miettinen, Yves Pommier. Pharmacol Ther 2019
49
16

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.
C Allison Stewart, Carl M Gay, Yuanxin Xi, Santhosh Sivajothi, V Sivakamasundari, Junya Fujimoto, Mohan Bolisetty, Patrice M Hartsfield, Veerakumar Balasubramaniyan, Milind D Chalishazar,[...]. Nat Cancer 2020
49
16

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
J von Pawel, J H Schiller, F A Shepherd, S Z Fields, J P Kleisbauer, N G Chrysson, D J Stewart, P I Clark, M C Palmer, A Depierre,[...]. J Clin Oncol 1999
621
16

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Charles M Rudin, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet K Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin Yang,[...]. J Clin Oncol 2020
114
16

Establishment and identification of small cell lung cancer cell lines having classic and variant features.
D N Carney, A F Gazdar, G Bepler, J G Guccion, P J Marangos, T W Moody, M H Zweig, J D Minna. Cancer Res 1985
903
16

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Abbie S Ireland, Alexi M Micinski, David W Kastner, Bingqian Guo, Sarah J Wait, Kyle B Spainhower, Christopher C Conley, Opal S Chen, Matthew R Guthrie, Danny Soltero,[...]. Cancer Cell 2020
64
16

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Helai P Mohammad, Kimberly N Smitheman, Chandrashekhar D Kamat, David Soong, Kelly E Federowicz, Glenn S Van Aller, Jess L Schneck, Jeffrey D Carson, Yan Liu, Michael Butticello,[...]. Cancer Cell 2015
273
16

DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
J T Poirier, E E Gardner, N Connis, A L Moreira, E de Stanchina, C L Hann, C M Rudin. Oncogene 2015
125
16

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Triparna Sen, Pan Tong, Lixia Diao, Lerong Li, Youhong Fan, Jennifer Hoff, John V Heymach, Jing Wang, Lauren Averett Byers. Clin Cancer Res 2017
57
16

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Lauren Averett Byers, Jing Wang, Monique B Nilsson, Junya Fujimoto, Pierre Saintigny, John Yordy, Uma Giri, Michael Peyton, You Hong Fan, Lixia Diao,[...]. Cancer Discov 2012
295
16

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Gabriele Zoppoli, Marie Regairaz, Elisabetta Leo, William C Reinhold, Sudhir Varma, Alberto Ballestrero, James H Doroshow, Yves Pommier. Proc Natl Acad Sci U S A 2012
152
16

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Anna F Farago, Beow Y Yeap, Marcello Stanzione, Yin P Hung, Rebecca S Heist, J Paul Marcoux, Jun Zhong, Deepa Rangachari, David A Barbie, Sarah Phat,[...]. Cancer Discov 2019
60
16

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji,[...]. Lancet 2019
460
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.